ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded at StockNews.com

StockNews.com upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a sell rating to a hold rating in a report issued on Wednesday morning.

A number of other analysts also recently commented on ANIP. Truist Financial boosted their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. HC Wainwright reissued a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Piper Sandler started coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective for the company. Leerink Partners started coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price on the stock. Finally, Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $60.55 on Wednesday. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -110.09 and a beta of 0.74. The business’s 50 day moving average is $56.64 and its two-hundred day moving average is $58.51. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The firm had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. ANI Pharmaceuticals’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.05 earnings per share. Research analysts expect that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Insider Transactions at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now owns 370,378 shares in the company, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now owns 154,468 shares of the company’s stock, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,381 shares of company stock valued at $2,441,556 over the last three months. 12.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. US Bancorp DE lifted its position in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after buying an additional 531 shares during the period. KBC Group NV lifted its holdings in shares of ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after acquiring an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ANI Pharmaceuticals by 24.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after acquiring an additional 579 shares during the last quarter. HighTower Advisors LLC purchased a new stake in ANI Pharmaceuticals in the third quarter valued at approximately $222,000. Finally, China Universal Asset Management Co. Ltd. increased its position in ANI Pharmaceuticals by 64.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company’s stock worth $241,000 after purchasing an additional 1,582 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.